Routine double-ovarian-stimulation (DuoStim) in poor responders lacks rationale, evidence, and follow-up

Angelo Tocci, David Barad, Krzysztof Łukaszuk, Raoul Orvieto

Research output: Contribution to journalArticlepeer-review


Double ovarian stimulation (DuoStim), initially only suggested for fertility preservation in cancer patients, is now increasingly also used in routine clinical IVF, especially in poor responders. The claimed rational for this is the alleged existence of multiple follicular waves in a single intermenstrual interval, allowing for retrieval of more oocytes in a single IVF cycle. This commentary argues that this expansion of purpose lacks rationale, evidence, and follow-up. Consequently, we suggest that, unless valid clinical indications have been established, DuoStim be only subject of controlled clinical trials with appropriate experimental consents.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalHuman Reproduction
Issue number3
StatePublished - 1 Mar 2023


  • DuoStim
  • IVF-ET
  • double-ovarian-stimulation
  • evidence
  • follow-up
  • live birth rate
  • ovarian stimulation
  • poor ovarian response
  • rational


Dive into the research topics of 'Routine double-ovarian-stimulation (DuoStim) in poor responders lacks rationale, evidence, and follow-up'. Together they form a unique fingerprint.

Cite this